2026-04-30
Blue Ocean Capital Group (BOCG) today announced that, as part of its strategy to further deepen its footprint and sharpen its focus in the life sciences sector, its Shenzhen headquarters and affiliated incubation platform Youjoy Incubator will officially relocate Guangming Technology Finance Towerin in Guangming Science City, effective May 1, 2026.This move represents a critical shift of BOCG’s strategic move toward the source of innovation. By embedding itself into one of the world’s leading hubs for life sicence R&D, BOCG aims to strengthen its early-stage enabling capabilities and value-creation partnerships at the forefront of life sciences.
As a core component of the Guangdong-Hong Kong-Macao Greater Bay Area’s comprehensive National Science Center, Guangming Science City is already home to two world-class large-scale scientific facilities — the Synthetic Biology Research Facility and the Brain Analysis and Brain Simulation Facility. It has also built a robust innovation matrix anchored by national strategic science and technology forces, including the Shenzhen Institute of Advanced Technology (SIAT) of the Chinese Academy of Sciences, Shenzhen Medical Academy of Research and Translation (SMART), Shenzhen Bay Laboratory, and Shenzhen University of Advanced Technology. BOCG will leverage this integrated ecosystem to intensify itsfocus on early-stage, high-impact technologies in areas such as brain-computer interfaces, neuroscience，breakthrought herapeutics, and AI-enabled medical technologies.
As avenutre capital investment firm dedicated to life sciences, BOCG has always supported original innovation in this field — across multiple frontiers including brain science, brain-computer interfaces, neuromodulation, synthetic biology, and AI-empowered drug discovery. Through active investment, BOCG facilitates the translation of scientific breakthroughs into commercial applications and nurtures early-stage ventures.The relocation of its Shenzhen headquarters and Youjoy Incubator to Guangming Science City marks a key step in BOCG’s integrated “investing–incubating–co-creating” strategy. With capital as a driving force, BOCG will continue discovering and investing in companies with disruptive technological potential, advancing scientific innovation and industrial development to benefit patients worldwide.
